Variable | TNFi persistence | Time to remission | ||||||
---|---|---|---|---|---|---|---|---|
Univariate (n=497) | Multivariate (n=495) | Univariate (n=380) | Multivariate (n=379) | |||||
HR | p Value | HR | p Value | HR | p Value | HR | p Value | |
Used multivariate analysis | ||||||||
Age, years | 1.000 | 0.99 | 0.997 | 0.66 | 0.991 | 0.11 | 0.999 | 0.86 |
Sex, female vs male | 1.279 | 0.13 | 1.256 | 0.18 | 0.744 | 0.046 | 0.826 | 0.21 |
Initial therapy, combination vs monotherapy | 0.948 | 0.73 | 0.956 | 0.78 | 1.090 | 0.56 | 1.153 | 0.35 |
BMI, kg/m2 | 1.030 | 0.01 | 1.011 | 0.44 | 0.940 | <0.001 | 0.955 | <0.001 |
CDAI, point value | 1.037 | <0.001 | 1.027 | 0.001 | 0.944 | 0.002 | 0.964 | 0.052 |
mHAQ, point value | 2.307 | <0.001 | 1.585 | 0.049 | 0.257 | <0.001 | 0.478 | 0.008 |
PsA duration, years | 0.978 | 0.04 | 0.982 | 0.10 | 0.999 | 0.93 | 0.997 | 0.77 |
Alcohol use, yes vs no | 0.913 | 0.57 | 1.013 | 0.97 | 1.265 | 0.11 | 0.953 | 0.76 |
Smoking, ever vs never | 1.015 | 0.89 | 0.851 | 0.14 | ||||
Univariate: demographics | ||||||||
Ethnicity, Hispanic vs non-Hispanic* | 0.259 | 0.003 | 0.777 | 0.44 | ||||
Univariate: disease activity or disability | ||||||||
Swollen joints, number | 1.042 | 0.034 | 0.944 | 0.01 | ||||
Tender joints, number | 1.084 | <0.001 | 0.912 | 0.01 | ||||
Physician global assessment of disease activity, point value | 1.016 | 0.001 | 0.978 | 0.001 | ||||
Patient global assessment of disease activity, point value | 1.011 | 0.001 | 0.976 | <0.001 | ||||
Physician global assessment of skin, point value* | 1.006 | 0.12 | 0.981 | <0.001 | ||||
Patient global assessment of skin, point value* | 1.011 | 0.001 | 0.991 | 0.04 | ||||
Univariate: medical history and risk factors | ||||||||
History of coronary artery disease, yes vs no* | 2.111 | 0.04 | 0.555 | 0.16 | ||||
History of MTX, yes vs no | 1.702 | 0.03 | 1.198 | 0.395 | ||||
History of hypertension, yes vs no | 1.267 | 0.18 | 0.505 | 0.001 | ||||
History of diabetes, yes vs no | 0.904 | 0.75 | 0.496 | 0.03 |
Variables presented in this table were either statistically significant in at least one univariate analysis or included in a multivariate analysis. Complete univariate and multivariate analysis tables (including 95% CIs for HRs) by analysis are presented in the online supplementary appendices tables S1 and S2. In the TNFi persistence analysis, an HR >1 indicates increased risk of therapy switch and, therefore, shorter TNFi persistence. In the time to remission analysis, an HR >1 indicates increased risk of achieving remission and, therefore, achieving remission faster. In the time to loss of remission after therapy switch analysis, an HR >1 indicates increased risk of losing remission and, therefore, shorter time to loss of remission.
*Values not recorded for patients enrolled early in the study. Updates to the enrolment form added variables.
BMI, body mass index; CDAI, Clinical Disease Activity Index; mHAQ, modified Health Assessment Questionnaire; MTX, methotrexate; NA, (data) not available; PsA, psoriatic arthritis; TNFi, tumour necrosis factor inhibitor.